23 Jun Determinants for Use of GLP-1 Receptor Agonists
Posted at 13:03h
in
Determinants for Use of GLP-1 Receptor Agonists
OS0019
Overview
Background
- In recent years, increased uptake in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has contributed to shortages of these medicines around the world, including in Canada.
- GLP-1 RAs are either authorized for managing hyperglycemia in patients with type 2 diabetes mellitus or for weight management under certain conditions.
- Off-label use has raised concerns. This relates to use for weight management in people without obesity or in people without overweight who do not have weight-related health problems.
Objectives
- This is a collaboration study with the International Coalition of Medicine Regulatory Authorities (ICMRA). We will replicate a study conducted by DARWIN EU (EUPAS1000000828).
- The study aims to describe characteristics of patients prescribed a GLP-1 RA and patterns of use between 2015 and 2025, including switching between substances and to other antidiabetic medications, as well as switching between selected brands.